Brief: MaxCyte Inc FY Revenue $16.7 Mln
24/04/2019 07:40
April 24 (Reuters) - MaxCyte Inc MXCT.L :
* FY REVENUE $16.7M VERSUS $14.0M
* MAXCYTE'S BOARD ANTICIPATES CONTINUED PROGRESS AND STRONG
GROWTH
IN 2019 FINANCIAL YEAR IN LINE WITH EXPECTATIONS
Source text for Eikon: ID:nRSX8683Wa
Further company coverage: MXCT.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MaxCyte
See all newsMaxCyte, Inc. MaxCyte, Inc. - MXCR - Second Price Monitoring Extn
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Price Monitoring Extension
Brief: Maxcyte And Allogene Therapeutics Sign Clinical And Commercial License Agreement To Enable The Advancement Of Allogeneic Car T (Allocar T™) Therapies
Brief: Maxcyte Signs Agreement With KSQ Therapeutics
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Agreement with KSQ Therapeutics